[
  {
    "ts": "2025-06-27T12:06:52+00:00",
    "headline": "The 5 Most Interesting Analyst Questions From Viatris’s Q1 Earnings Call",
    "summary": "Viatris' first quarter results for 2025 were met with a positive market response, largely due to strong execution in its global branded portfolio and pipeline advancements, despite revenue coming in below consensus. Management highlighted robust growth in Europe and China, as well as progress in its portfolio of innovative medicines. CEO Scott Smith noted, “We were particularly pleased with our strong execution and growth in Europe and China this quarter,” attributing operational revenue decline",
    "url": "https://finance.yahoo.com/news/5-most-interesting-analyst-questions-120652359.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "283b2920-b43d-36f8-8b3e-63472466ddcb",
      "content": {
        "id": "283b2920-b43d-36f8-8b3e-63472466ddcb",
        "contentType": "STORY",
        "title": "The 5 Most Interesting Analyst Questions From Viatris’s Q1 Earnings Call",
        "description": "",
        "summary": "Viatris' first quarter results for 2025 were met with a positive market response, largely due to strong execution in its global branded portfolio and pipeline advancements, despite revenue coming in below consensus. Management highlighted robust growth in Europe and China, as well as progress in its portfolio of innovative medicines. CEO Scott Smith noted, “We were particularly pleased with our strong execution and growth in Europe and China this quarter,” attributing operational revenue decline",
        "pubDate": "2025-06-27T12:06:52Z",
        "displayTime": "2025-06-27T12:06:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VTRS Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kZ5PSZg5aKFn_8IHve8fGQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4bPZw8EZ18ugKQPfipbnLw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-most-interesting-analyst-questions-120652359.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-most-interesting-analyst-questions-120652359.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-27T11:36:33+00:00",
    "headline": "Viatris gains China approval for Yupelri to treat COPD",
    "summary": "Viatris will handle all development and commercialisation aspects of Yupelri in the Chinese market.",
    "url": "https://www.pharmaceutical-technology.com/news/viatris-china-approval-yupelri-copd/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "c782e0e3-9e50-310e-937b-3ecc80e88696",
      "content": {
        "id": "c782e0e3-9e50-310e-937b-3ecc80e88696",
        "contentType": "STORY",
        "title": "Viatris gains China approval for Yupelri to treat COPD",
        "description": "",
        "summary": "Viatris will handle all development and commercialisation aspects of Yupelri in the Chinese market.",
        "pubDate": "2025-06-27T11:36:33Z",
        "displayTime": "2025-06-27T11:36:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/719ef8a9e4e4283f350de88ad014a49f",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "Yupelri is approved in China for the maintenance treatment of chronic obstructive pulmonary disease. Credit: NMK-Studio / Shutterstock.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MEEllW9bUHu8fztq1HymVA--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/719ef8a9e4e4283f350de88ad014a49f.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lTlpTTHlDFCz8b.EFf7uog--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/719ef8a9e4e4283f350de88ad014a49f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/viatris-china-approval-yupelri-copd/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-gains-china-approval-yupelri-113633102.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            },
            {
              "symbol": "TBPH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-27T09:24:54+00:00",
    "headline": "Viatris’ presbyopia drug clears second Phase III trial",
    "summary": "There are only two therapies approved for presbyopia in the US.",
    "url": "https://www.clinicaltrialsarena.com/news/viatris-presbyopia-drug-clears-second-phase-iii-trial/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "532a0bf3-dc08-3077-8bbe-5bbf18baac90",
      "content": {
        "id": "532a0bf3-dc08-3077-8bbe-5bbf18baac90",
        "contentType": "STORY",
        "title": "Viatris’ presbyopia drug clears second Phase III trial",
        "description": "",
        "summary": "There are only two therapies approved for presbyopia in the US.",
        "pubDate": "2025-06-27T09:24:54Z",
        "displayTime": "2025-06-27T09:24:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/7d0271df75360a7008a6c5bbc8fae50a",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "Viatris has announced data form a second Phase III trial of its therapy for presbyopia. Image credit: TeodorLazarev / Shutterstock.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bkNgpGFzPMZlANJRO8IIwA--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/7d0271df75360a7008a6c5bbc8fae50a.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kg74K1NcMxINh2dFbCM.3Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/7d0271df75360a7008a6c5bbc8fae50a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/viatris-presbyopia-drug-clears-second-phase-iii-trial/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-presbyopia-drug-clears-second-092454287.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]